Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.62. Protagenic Therapeutics shares last traded at $0.65, with a volume of 61,694 shares traded.
Protagenic Therapeutics Stock Performance
The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.47 and a quick ratio of 19.47.
Get Protagenic Therapeutics alerts:Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 11.09% of the stock is currently owned by institutional investors and hedge funds.
About Protagenic Therapeutics
(Get Rating)Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Featured Articles
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.